A Phase 2 interventional study of Placebo and Treprostinil Inhalation Solution 36 mcg in COPD (Chronic Obstructive Pulmonary Disease), sponsored by University of Alberta. Active, not recruiting at 1 site in Canada. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by University of Alberta · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pulmonary Disease, Chronic Obstructive by University of Alberta — 2 open to participants now, 3 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University of Alberta.
Among the 17 studies in Pulmonary Disease, Chronic Obstructive by University of Alberta, this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 2, and was the 17th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by University of Alberta are open now, in 1 country. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 40–80 · Healthy volunteers
University of Alberta
Ages 18–85 · Healthy volunteers
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 80 across the 13 interventional studies, 162 across the 4 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
2 of the studies in Pulmonary Disease, Chronic Obstructive by University of Alberta that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06969573University of AlbertaInhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD | 2026-12-31 |
| NCT05061368University of AlbertaOral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Pulmonary Disease, Chronic Obstructive by University of Alberta, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to:
The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity
The study consists of 6 visits (5 to the Clinical Sciences Building at the University of Alberta):
Day 1: participants will provide informed consent, medical history and health screening (Physical activity readiness questionnaire [PAR-Q+], COPD assessment test [CAT], modified medical research council [mMRC], euro quality of life- 5 dimensions [EQ-5D]), be familiarized to the laboratory and experimental measurement protocols, conduct a pulmonary function test, and conduct an incremental CPET to determine peak oxygen consumption (V̇O2peak) on the cycle ergometer. Throughout exercise, non-invasive measurements of cardiac output (impedance cardiography), heart rate (electrocardiogram), expired gases (metabolic cart), and oxygen saturation (pulse oximetry) will be completed. A small blood sample will be collected via finger prick to measure hemoglobin (to correct DLCO - part of the pulmonary function test). Ratings of perceived breathing and leg discomfort (Borg scale), as well as dimensional descriptors of dyspnea scales will be recorded throughout the exercise test, and immediately upon exercise cessation.
Days 2-4: participants will complete resting, seated, DLCO maneuvers as well as a constant workload (75% of the peak power output determined from the CPET) cycling exercise test until volitional fatigue (i.e., exhaustion) with or without inhaled Treprostinil (placebo, 36, or 78 mcg; via Tyvaso® Inhalation Solution). DLCO and its components will be evaluated by standardized multiple breath-hold technique. A small blood sample will be collected via finger prick to measure hemoglobin for the DLCO maneuvers prior to and following exercise. Throughout exercise, non-invasive measurements of cardiac output (impedance cardiography), heart rate (electrocardiogram), expired gases (metabolic cart), and oxygen saturation (pulse oximetry) will be completed. Additionally, ratings of perceived breathing and leg discomfort (Borg scale), as well as dimensional descriptors of dyspnea scales will be recorded throughout the exercise test, and immediately upon exercise cessation. The drug condition (placebo, 36, or 78 mcg) will be randomized (block randomization) by a member of our research team who is not involved in data analysis or collection.
Day 5: participants will complete supine DLCO maneuvers (multiple breath-hold technique) as well as resting echocardiography (to measure pulmonary artery and cardiac function) with and without inhaled Treprostinil (placebo, 36, and 78 mcg). A small blood sample will be collected via finger prick to measure hemoglobin for the DLCO maneuvers.
Day 6: participants will undergo a low contrast CT scan of their chest for quantification of pulmonary vascular volumes (i.e., blood vessel volume in the lungs). No drug intervention will be completed on Day 6.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will inhale placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer
Drug: Placebo
Participants will inhale 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
Combination Product: Treprostinil Inhalation Solution 36 mcg
Participants will inhale 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
Combination Product: Treprostinil Inhalation Solution 78 mcg
Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer
Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
Exercise tolerance
Time to symptom limitation/exhaustion during a constant work rate test.
Time frame: Within 30-45 minutes post dose
Exertional dyspnea
Maximal perceived breathing discomfort during exercise
Time frame: Within 30-45 minutes post dose
Ventilatory efficiency
Nadir value of the ratio between ventilation and the rate of CO2 production (Ve/VCO2 nadir)
Time frame: Within 30-45 minutes post dose
Lung diffusing capacity
Lung diffusing capacity (DLCO) will be measured using six-second, advanced DLCO techniques.
Time frame: Within 15-30 minutes post dose
Pulmonary capillary blood volume (Vc)
Pulmonary capillary blood volume (Vc) will be measured using six-second, advanced DLCO techniques.
Time frame: Within 15-30 minutes post dose
Diffusing membrane Capacity (Dm)
Diffusing membrane capacity will be measured using six-second, advanced DLCO techniques.
Time frame: Within 15-30 minutes post dose
Cardiac structure and function
echocardiography-derived right ventricular systolic pressure
Time frame: Within 15-30 minutes post dose
Pulmonary vascular volumes
Chest computed tomography (CT) scan
Time frame: Day 6
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
Of 47 non-industry phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's planned 18 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →